Search Results for keywords:"Drug Enforcement Administration"

Noramco has submitted an application to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company specifically plans to produce active pharmaceutical ingredients, including synthetic marihuana and tetrahydrocannabinols. Individuals or organizations can submit comments or objections to this application by March 25, 2025, through the Federal eRulemaking Portal. The announcement provides further details about the application and the procedures for submitting feedback.

The Drug Enforcement Administration (DEA) has revoked the DEA Certificate of Registration for Herold Pierre-Louis, a physician assistant from Tucson, Arizona. This decision stems from the Arizona Regulatory Board of Physician Assistants revoking Pierre-Louis's license, leaving him unable to legally handle controlled substances in Arizona. The DEA's ruling is based on federal law, which requires practitioners to have state authorization to dispense controlled substances. Without this state license, Pierre-Louis cannot maintain his federal registration, and all pending applications for his registration have been denied.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Dr. Matthew Okeke, who is based in Nevada. This order proposed revoking his DEA registration because he no longer has a valid state license or authority to handle controlled substances in Nevada. Dr. Okeke did not respond to the order, leading the DEA to proceed with final agency action to revoke his registration. The decision was signed by DEA Administrator Anne Milgram and is set to take effect on January 29, 2025.

Restek Corporation has applied to the Drug Enforcement Administration (DEA) to become a registered importer of certain controlled substances. These substances will be imported for use in manufacturing certified reference materials. The public can submit comments or objections to this application by April 28, 2025, through the Federal eRulemaking Portal. Approval will be granted only if the importation activities comply with legal requirements, with no permission for importing finished drug products for commercial sale.

Promega Corporation has applied to the Drug Enforcement Administration to register as a bulk manufacturer of certain controlled substances. This notice invites comments or objections to the proposed registration by May 27, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal at regulations.gov. The substances will be manufactured as Active Pharmaceutical Ingredients for sale to customers, with no other uses authorized.

The Drug Enforcement Administration (DEA) has announced that Ohana Bio Pharma, LLC has applied to be registered as a bulk manufacturer of controlled substances in schedule I, specifically for marihuana. This application is part of a program to grow marihuana for scientific and medical research. The DEA will evaluate the application according to its regulations to ensure legal compliance and prevent any misuse. Interested parties can submit their comments or objections by May 27, 2025, through the Federal eRulemaking Portal.

Siegfried USA, LLC, located in New Jersey, has submitted an application to become an importer of specific controlled substances, as noted by the Drug Enforcement Administration (DEA). The company plans to import these substances to create active pharmaceutical ingredients for its clients, specifically using Phenylacetone to produce Amphetamine. Comments or objections regarding this application are invited by March 18, 2021, and requests for a hearing can also be made by this date. Final permit approval will align with conditions outlined under the relevant U.S. Code and does not permit the commercial import of drug forms approved or non-approved by the Food and Drug Administration (FDA).

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Dr. Milad I. Shaker due to his lack of authority to handle controlled substances in Pennsylvania. This decision followed the suspension of his medical license in Pennsylvania after he was found noncompliant with probation terms and was convicted of unlawfully distributing a controlled substance. Dr. Shaker did not request a hearing or submit a corrective action plan, leading to the automatic waiver of these rights. As a result, his registration has been revoked, and any pending applications to renew or modify this registration have been denied.

Siegfried USA, LLC has submitted an application to the Drug Enforcement Administration (DEA) seeking approval to become an importer of certain controlled substances. The application is intended to allow the company to import these substances for the purpose of manufacturing bulk Active Pharmaceutical Ingredients for its customers. Interested parties, such as registered bulk manufacturers of these controlled substances, are invited to submit comments or objections to this application by January 29, 2025. Comments should be submitted electronically via the Federal eRulemaking Portal, and requests for a hearing can be sent to the DEA at the addresses provided in the document.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on its information collection proposal related to electronic prescriptions for controlled substances. This collection is critical for verifying practitioners' identities and managing their access to prescription systems securely. Affected groups include businesses, non-profits, and government entities, required to respond mandatorily. The DEA estimates that the total annual time burden for respondents will be 107,733 hours, with no additional cost burdens. Comments on the proposal will be accepted until March 3, 2025.